| Heading: |
Givinostat |
| Question ID: |
1811753 |
| UIN: |
59235 |
| House: |
Commons |
| Date tabled: |
2025-06-11 |
| Asking Member ID: |
5283 |
| Asking Member display name: |
Alison Bennett
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Alison Bennett
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the availability of givinostat to patients eligible through early access programmes. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-18 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Department understands the impact that Duchenne muscular dystrophy has on those living with it, and their families, and the urgent need for new treatment options. If new therapies for Duchenne muscular dystrophy are approved by the National Institute ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |